SLC5A2 and type 2 diabetes mellitus: The meta-analysis of data from four CVOTs and two trials of kidney outcomes with SGLT2 inhibitors in patients with T2D or CKD showed a significant reduction in the risk of serious hyperkalemia (≥6.0 mmol/L) by 16% without any heterogeneity across the trials [51].